Sign in
VYNE Stock Price, Chart, Stats & News
VYNE Therapeutics Inc.
Save
10.93M
Market cap
–
Current P/E
–
Forward P/E
VYNE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.12% |
Operating margin | -5219.12% |
Pretax margin | -4689.82% |
Net margin | -4646.14% |
Effective tax rate | -0.01% |
ROA | -87.81% |
ROE | -74.15% |
D/E | – |
Interest coverage ratio | – |
VYNE valuation
P/E | – |
P/S | 17.28x |
P/B | 0.91x |
P/CF | -0.76x |
P/FCF | -0.30x |
P/OCF | -0.76x |
PEG | -0.05x |
EV multiple | -1.15x |
About
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
Similar securities
Based on sector and market capitalization
Report issue